At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 680 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.
In Brief
A Phase 3 clinical trial evaluating Placebo and Vilazodone for Generalized Anxiety Disorder. Completed, enrolled 680 participants across 37 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJun 2012
Primary CompletionFeb 2014
Study CompletionMar 2014
TodayJul 2026
First PostedJun 28, 2012
Enrollment StartJun 30, 2012
Primary CompletionFeb 28, 2014
Study CompletionMar 31, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.0 years ago
Interventions
Placebodrug
Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
Vilazodonedrug
Vilazodone, 20mg, oral administration once per day.
Vilazodonedrug
Vilazodone, 40mg, oral administration once per day.